Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat.
In rats, administration of a single dose of cysteamine (300 mg/kg, intragastrically) induces a depletion of pancreatic somatostatin content (approximately 60%) without modifying pancreatic insulin or glucagon content. In perfused pancreases from cysteamine-treated rats, there was a lack of somatostatin response to glucose, arginine or tolbutamide. In the absence of stimulated somatostatin release, the secretory responses of insulin and glucagon to glucose, to arginine, and to tolbutamide were not significantly different from those observed in pancreases from control rats. Our data do not support the concept that pancreatic somatostatin plays a major role in the control of insulin and glucagon release.
Silvestre
R A
RA
Miralles
P
P
Moreno
P
P
Villanueva
M L
ML
Marco
J
J
D000818:Animals; D001120:Arginine / Q000494:pharmacology; D003543:Cysteamine / Q000494:pharmacology*; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism*; D008297:Male; D010477:Perfusion; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000097:blood / Q000378:metabolism*; D014044:Tolbutamide / Q000494:pharmacology
D007328:Insulin; D013004:Somatostatin; D003543:Cysteamine; D005934:Glucagon; D001120:Arginine; D014044:Tolbutamide; D005947:Glucose